Extract from the Register for Unitary Patent Protection

UP About this file: EP4178584  C0

EP4178584 - HYDROXYAPATITE COMPOSITION COMPRISING ZOLEDRONIC ACID AND DOXORUBICIN FOR TREATING CANCER [Right-click to bookmark this link]
StatusUnitary effect registered
Database last updated on 14.09.2024
Most recent event   Tooltip30.08.2024New entry: Payment of renewal fee 
Proprietor(s)For all participating member states
Moroxite T AB
Kung Oscars väg 11c
222 35 Lund / SE
[2024/01]  
Inventor(s)01 / LIDGREN, Lars
298 31 TOLLARP / SE
02 / TÄGIL, Magnus
298 31 TOLLARP / SE
03 / RAINA, Deepak
298 31 TOLLARP / SE
04 / YANG, Liu
298 31 TOLLARP / SE
 [2023/20]
Representative(s)Zacco Sweden AB
P.O. Box 5581
Löjtnantsgatan 21
114 85 Stockholm / SE
[2024/01]
Application number, filing date21793863.805.10.2021
[2023/20]
WO2021EP77420
Procedural languageEN
(Principal) place of business   Tooltip
on the date of filing
 Principal place of businessTooltip
Unitary Patent Protection23.11.2023Date of request for unitary effect [2023/52]
29.11.2023Decision on the request for unitary effect:  Positive [2024/01]
29.11.2023Date of registration  [2024/01]
25.10.2023Date of legal effect  [2024/01]
Member States covered by Unitary  Tooltip
Patent Protection
29.11.2023AT, BE, BG, DE, DK, EE, FI, FR, IT, LT, LU, LV, MT, NL, PT, SE, SI  [2024/01]
PublicationType: B1 Patent specification 
No.:EP4178584
Date:25.10.2023
Language:EN
[2023/43]
Renewal fees paidRenewal fee
28.08.2024Renewal fee unitary effect year  04
The European Patent Register provides the information on unitary patent protection required under R. 16(1) UPR. "Status" and "Most recent event" are not entries required under R. 16(1) UPR and should therefore be regarded as additional information only.

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes. Please refer to the relevant national patent authority for SPC data.